Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to 2022 ACR/EULAR criteria
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study applied the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients with systemic sclerosis (SSc) and investigated the frequency of overlap syndrome of SSc and AAV (SSc-AAV-OS). Methods: Among the 232 patients diagnosed with SSc, 105 with signs suggestive of small- or medium-vessel vasculitis, which were defined as the present of interstitial lung disease (ILD), peripheral neuropathy, or suspected renal vasculitis, were included in this study and analyzed. Results: Among the 105 SSc patients, the detection rate of ANCA was 19.0%. When the 2022 ACR/EULAR criteria were applied, the frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported with previous criteria for AAV. ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis. Conclusions: The frequency of SSc-AAV-OS in SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0%. Therefore, we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.
Abstract
Background/Aims: This study applied the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients with systemic sclerosis (SSc) and investigated the frequency of overlap syndrome of SSc and AAV (SSc-AAV-OS). Methods: Among the 232 patients diagnosed with SSc, 105 with signs suggestive of small- or medium-vessel vasculitis, which were defined as the present of interstitial lung disease (ILD), peripheral neuropathy, or suspected renal vasculitis, were included in this study and analyzed. Results: Among the 105 SSc patients, the detection rate of ANCA was 19.0%. When the 2022 ACR/EULAR criteria were applied, the frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported with previous criteria for AAV. ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis. Conclusions: The frequency of SSc-AAV-OS in SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0%. Therefore, we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.
참고문헌 (24)
- Denton CP, "Systemic sclerosis", Lancet, 390, pp.1685~1699 (2017)
- Jennette JC, "2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides", Arthritis Rheum, 65, pp.1~11 (2013)
- Watts R, "Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies", Ann Rheum Dis, 66, pp.222~227 (2007)
- Kant S, "ANCA-associated vasculitis in scleroderma : a renal perspective", Clin Nephrol, 90, pp.413~418 (2018)
- Wu R, "ANCA-associated vasculitis overlaps with systemic sclerosis : a case report and literature review", Eur J Med Res, 26, pp.30~ (2021)
- Moxey J, "Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis", Arthritis Res Ther, 21, pp.57~ (2019)
- Radwan Y, "Proteinase 3(PR3)-antineutrophil cytoplasmic antibody(ANCA)-associated vasculitic neuropathy in diffuse cutaneous systemic sclerosis : a rare duo", BMJ Case Rep, 12, pp.e232987~ (2019)
- Ha JW, "Significance of antineutrophil cytoplasmic antibody positivity in patients with systemic sclerosis : a single-centre pilot study in Korea", Clin Exp Rheumatol, 39(Suppl 131), pp.111~118 (2021)
- Suppiah R, "2022 American College of Rheumatology", European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis, 2022, pp.81, 321~326
- Robson JC, "2022 American College of Rheumatology", European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis, 2022, pp.81, 315~320
- Grayson PC, "2022 American College of Rheumatology", European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis, 2022, pp.81, 309~314
- van den Hoogen F, "2013 classification criteria for systemic sclerosis : an American college of rheumatology", European league against rheumatism collaborative initiative, 2013, pp.72, 1747~1755
- Do H, "Cancer-associated vasculitides : a single-centre case series", Clin Rheumatol, 42, pp.151~158 (2023)
- Phatak S, "Antineutrophil cytoplasmic antibody(ANCA)testing : audit from a clinical immunology laboratory", Int J Rheum Dis, 20, pp.774~778 (2017)
- Lee WI, "The significance of ANCA positivity in patients with inflammatory bowel disease", Pathology, 51, pp.634~639 (2019)
- Wong AH, "Propylthiouracil-induced antineutrophil cytoplasmic antibodies-associated vasculitis with renal and lung involvement", Case Rep Nephrol Dial, 12, pp.105~111 (2022)
- Alawneh D, "Hydralazine-induced antineutrophil cytoplasmic antibody(ANCA)-associated vasculitis : a case report and literature review", Cureus, 14, pp.e24132~ (2022)
- Bossuyt X, "Position paper : revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis", Nat Rev Rheumatol, 13, pp.683~692 (2017)
- Choi CB, "Antineutrophil cytoplasmic antibody-associated vasculitis in Korea : a narrative review", Yonsei Med J, 60, pp.10~21 (2019)
- Kitching AR, "ANCA-associated vasculitis", Nat Rev Dis Primers, 6, pp.71~ (2020)
- Quéméneur T, "Systemic vasculitis during the course of systemic sclerosis : report of 12 cases and review of the literature", Medicine(Baltimore), 92, pp.1~9 (2013)
- Asano Y, "Vasculopathy in scleroderma", Semin Immunopathol, 37, pp.489~500 (2015)
- Ha JW, "Incidence and patterns of interstitial lung disease and their clinical impact on mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis : Korean single-centre observational study", J Immunol Res, 2022, pp.2499404~ (2022)
- Ha JW, "A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis", Sci Rep, 12, pp.19253~ (2022)